Beam Therapeutics’ Promising BEACON Trial and Advanced Manufacturing Boost Buy Rating

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Beam Therapeutics today and set a price target of $80.00.

Patrick Trucchio has given his Buy rating due to a combination of factors, primarily centered around the promising data from Beam Therapeutics’ BEACON trial. The trial showcased risto-cel’s potential as a next-generation precision medicine for sickle cell disease (SCD), highlighting its ability to correct hemoglobin levels, resolve anemia, and prevent vaso-occlusive crises. These results, presented at the ASH 2025 meeting, underscore the therapy’s efficacy and safety, reinforcing its differentiated profile in the treatment of SCD.
Additionally, the enhanced manufacturing process for risto-cel, which includes an efficient ‘vein-to-vein’ timeline, positions Beam Therapeutics with a competitive advantage in the ex vivo hematology space. The consistency and scalability of this process, along with the robust clinical data, support the therapy’s potential to become a best-in-class autologous cell therapy. This positions Beam well for future regulatory discussions and potential market readiness, justifying the Buy rating and the $80 price target.

In another report released today, Wedbush also maintained a Buy rating on the stock with a $57.00 price target.